Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications
Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment.
Journal: The New England journal of medicine
Published: July 29, 2026
Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
Journal: The lancet. HIV
Published: March 17, 2026
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.
Journal: Annals of internal medicine
Published: December 22, 2025
Safety and Tolerability of Oral Islatravir Once Monthly as Pre-exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 28, 2025
Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 28, 2025
Safety, Pharmacokinetics, and Pharmacodynamics of Single-Dose Programmed Cell Death Protein 1 Inhibitor, Budigalimab, in People With HIV-1 With Antiretroviral Therapy-Suppressed Viral Load.
Journal: The Journal of infectious diseases
Published: June 03, 2025
Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV.
Journal: AIDS research and therapy
Published: January 28, 2025
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.
Journal: The New England journal of medicine
Published: November 27, 2024
Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab.
Journal: The Journal of infectious diseases
Published: November 15, 2024
A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist Vesatolimod.
Journal: Infectious diseases and therapy
Published: July 12, 2024
HIV rebound in HIV controllers is associated with a specific fecal microbiome profile.
Journal: European journal of immunology
Published: February 27, 2024
Last Updated: 09/26/2026